We should use PDL1 and other biomarkers for selecting patients for immune checkpoint therapies

Share :
Sorry, this item is currently unavailable.
Published: 5 Oct 2016
Views: 1577
Rating:
Save
Dr Mary O’Brien - The Royal Marsden NHS Foundation Trust, London, UK

Dr O’Brien presents us with the arguments for using PDL1 and other biomarkers for selecting patients for immune checkpoint therapies, during the Controversies in NSCLC session at the Future Horizons in Lung Cancer meeting.